Back to User profile » Dr Angelo Ruggiero
Papers published by Dr Angelo Ruggiero:
Effectiveness and Safety of Tildrakizumab in Elderly and Frail Elderly Psoriatic Patients Up to 2 years
Mastorino L, Dapavo P, Burlando M, Gisondi P, Maronese CA, Ruggiero A, Galluzzo M, Pisani MC, Sacchelli L, Caldarola G, Avallone G, Marzano AV, Megna M, Campione E, Loconsole F, Bardazzi F, De Simone C, Quaglino P, Ribero S
Psoriasis: Targets and Therapy 2025, 15:339-350
Published Date: 4 August 2025
A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab [Corrigendum]
Megna M, Ruggiero A, Salsano A, Lauletta G, Portarapillo A, Torta G, Martora F, Potestio L
Clinical, Cosmetic and Investigational Dermatology 2024, 17:1447-1448
Published Date: 18 June 2024
Secukinumab for Severe Hidradenitis Suppurativa in a Patient on Haemodialysis: Efficacy and Safety on 300 mg Every 2 Weeks Administration – A Case Report
Martora F, Annunziata MC, Potestio L, Battista T, Ruggiero A, Megna M
Clinical, Cosmetic and Investigational Dermatology 2024, 17:1275-1279
Published Date: 30 May 2024
Effectiveness and Safety of Tildrakizumab in Psoriasis Patients Who Failed Anti-IL17 Treatment: A 28-Week Real-Life Study
Megna M, Ruggiero A, Tommasino N, Brescia C, Martora F, Cacciapuoti S, Potestio L
Clinical, Cosmetic and Investigational Dermatology 2024, 17:1037-1042
Published Date: 7 May 2024
The Past, the Present and the Future of Teledermatology: A Narrative Review
Tommasino N, Megna M, Cacciapuoti S, Villani A, Martora F, Ruggiero A, Genco L, Potestio L
Clinical, Cosmetic and Investigational Dermatology 2024, 17:717-723
Published Date: 21 March 2024
L-Lysine as an Alternative Treatment for Pityriasis Rosea (PR) [Response to Letter]
Potestio L, Martora F, Cacciapuoti S, Megna M, Villani A, Ruggiero A
Clinical, Cosmetic and Investigational Dermatology 2024, 17:463-464
Published Date: 24 February 2024
Pityriasis Rosea and Pityriasis Rosea-Like Eruption Following COVID-19 Vaccination: A Narrative Review
Potestio L, Martora F, Cacciapuoti S, Megna M, Villani A, Ruggiero A
Clinical, Cosmetic and Investigational Dermatology 2024, 17:51-57
Published Date: 8 January 2024
A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab
Megna M, Ruggiero A, Salsano A, Lauletta G, Portarapillo A, Torta G, Martora F, Potestio L
Clinical, Cosmetic and Investigational Dermatology 2023, 16:3503-3507
Published Date: 5 December 2023
Management Strategies for Pediatric Moderate-to-Severe Plaque Psoriasis: Spotlight on Biologics
Ruggiero A, Portarapillo A, Megna M, Patruno C, Napolitano M
Pediatric Health, Medicine and Therapeutics 2023, 14:435-451
Published Date: 14 November 2023
JAK Inhibitors in Psoriatic Disease
Megna M, Potestio L, Ruggiero A, Cacciapuoti S, Maione F, Tasso M, Caso F, Costa L
Clinical, Cosmetic and Investigational Dermatology 2023, 16:3129-3145
Published Date: 31 October 2023
Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat Areas
Cacciapuoti S, Potestio L, Guerrasio G, Fabbrocini G, Scalvenzi M, Ruggiero A, Caiazzo G, Megna M
Clinical, Cosmetic and Investigational Dermatology 2023, 16:2637-2644
Published Date: 25 September 2023
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data
Martora F, Scalvenzi M, Battista T, Fornaro L, Potestio L, Ruggiero A, Megna M
Clinical, Cosmetic and Investigational Dermatology 2023, 16:2525-2536
Published Date: 18 September 2023
Biologics for the Management of Erythrodermic Psoriasis: An Updated Review
Potestio L, Camela E, Cacciapuoti S, Fornaro L, Ruggiero A, Martora F, Battista T, Megna M
Clinical, Cosmetic and Investigational Dermatology 2023, 16:2045-2059
Published Date: 4 August 2023
Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?
Megna M, Camela E, Ruggiero A, Battista T, Martora F, Cacciapuoti S, Potestio L
Clinical, Cosmetic and Investigational Dermatology 2023, 16:1677-1690
Published Date: 28 June 2023
Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature
Potestio L, Ruggiero A, Fabbrocini G, Martora F, Megna M
Psoriasis: Targets and Therapy 2023, 13:19-26
Published Date: 4 May 2023
Injections Site Reactions and Biologics for Psoriasis: A Questionnaire Based Real Life Study
Matteo M, Battista T, Noto M, Picone V, Fabbrocini G, Ruggiero A, Genco L
Clinical, Cosmetic and Investigational Dermatology 2023, 16:553-564
Published Date: 2 March 2023
Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study
Ruggiero A, Fabbrocicni G, Cacciapuoti S, Potestio L, Gallo L, Megna M
Clinical, Cosmetic and Investigational Dermatology 2023, 16:529-536
Published Date: 27 February 2023
Efficacy and Safety of Tildrakizumab in a Patient with Chronic HBV Infection
Potestio L, Piscitelli I, Fabbrocini G, Martora F, Ruggiero A, Megna M
Clinical, Cosmetic and Investigational Dermatology 2023, 16:369-373
Published Date: 5 February 2023
The Role of Teledermatology During the COVID-19 Pandemic: A Narrative Review
Ruggiero A, Martora F, Fabbrocini G, Villani A, Marasca C, Megna M, Fornaro L, Comune R, Potestio L
Clinical, Cosmetic and Investigational Dermatology 2022, 15:2785-2793
Published Date: 19 December 2022
Towards Personalized Medicine in Psoriasis: Current Progress
Camela E, Potestio L, Ruggiero A, Ocampo-Garza SS, Fabbrocini G, Megna M
Psoriasis: Targets and Therapy 2022, 12:231-250
Published Date: 1 September 2022
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence
Ruggiero A, Picone V, Martora F, Fabbrocini G, Megna M
Clinical, Cosmetic and Investigational Dermatology 2022, 15:1649-1658
Published Date: 16 August 2022
Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study
Megna M, Potestio L, Fabbrocini G, Ruggiero A
Psoriasis: Targets and Therapy 2022, 12:205-212
Published Date: 14 July 2022
Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge
Ruggiero A, Potestio L, Camela E, Fabbrocini G, Megna M
Psoriasis: Targets and Therapy 2022, 12:127-137
Published Date: 8 June 2022
Strategies to Improve Outcomes of Bullous Pemphigoid: A Comprehensive Review of Clinical Presentations, Diagnosis, and Patients’ Assessment
Ruggiero A, Megna M, Villani A, Comune R, Fabbrocini G, di Vico F
Clinical, Cosmetic and Investigational Dermatology 2022, 15:661-673
Published Date: 14 April 2022
The Efficacy and Safety of Abrocitinib as a Treatment Option for Atopic Dermatitis: A Short Report of the Clinical Data
Napolitano M, Fabbrocini G, Ruggiero A, Marino V, Nocerino M, Patruno C
Drug Design, Development and Therapy 2021, 15:1135-1147
Published Date: 10 March 2021